MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study

NAActive, not recruitingINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

September 20, 2022

Primary Completion Date

September 30, 2029

Study Completion Date

November 30, 2029

Conditions
Intracranial Aneurysm
Interventions
DEVICE

FRED™ X™

The FRED™ X™ System is indicated for use in the internal carotid artery from the petrous segment to the terminus for the endovascular treatment.

Trial Locations (25)

10029

Mount Sinai, New York

10467

Montefiore Medical Center, The Bronx

11030

Northwell Health, Manhasset

11794

Stony Brook University, Stony Brook

12208

Albany Medical Center, Albany

14203

University at Buffalo, Buffalo

19104

University of Pennsylvania, Philadelphia

19107

Thomas Jefferson University, Philadelphia

21201

University of Maryland, Baltimore

21287

The Johns Hopkins University, Baltimore

32806

Orlando Health, Orlando

33021

Memorial Healthcare Systems, Hollywood

40207

Baptist Healthcare System, Louisville

40241

Norton Healthcare, Louisville

43210

Ohio State University, Columbus

43214

Ohio Health Riverside Research Institute, Columbus

43606

ProMedica Toledo Hospital, Toledo

52242

University of Iowa, Iowa City

66160

University of Kansas, Kansas City

70121

Ochsner Health, New Orleans

73104

University of Oklahoma Health Sciences Center, Oklahoma City

77030

Houston Methodist Hospital, Houston

96813

Queen's Medical Center, Honolulu

02114

Massachusetts General Brigham Incorporated, Boston

01655

UMass Memorial Health, Worcester

All Listed Sponsors
lead

Microvention-Terumo, Inc.

INDUSTRY